David R. Liu

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

H. Kantarjian, J. Cortes, A. Quintás-Cardama, 2009, Cancer.

AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

J. Gribben, J. Leonard, I. Flinn, 2018, Blood.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma

G. Salles, L. Sehn, A. López-Guillermo, 2018, The New England journal of medicine.

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma

J. Gribben, J. Leonard, I. Flinn, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pregnancy Outcomes among Patients with Chronic Myeloid Leukemia Treated with Dasatinib

H. Kantarjian, J. Cortes, G. Borthakur, 2008 .

Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

J. Radich, L. Ploughman, M. Deininger, 2008 .

Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia

H. Kantarjian, J. Cortes, F. Ravandi, 2009, Cancer.

Importance of Early Intervention with Dasatinib at Cytogenetic Rather Than Hematologic Resistance to Imatinib.

H. Kantarjian, J. Cortes, F. Ravandi, 2007 .

Dasatinib 100 Mg Once Daily (QD) Maintains Long-Term Efficacy and Minimizes the Occurrence of Pleural Effusion: An Analysis of 24-Month Data in Patients with Resistance, Suboptimal Response, or Intolerance to Imatinib (CA180-034).

J. Cortes, R. Paquette, K. Porkka, 2008 .